Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bioventures In Japan Look Abroad To License Promising Drugs

This article was originally published in PharmAsia News

Executive Summary

Japanese bioventure firms are reversing a trend and beginning to license their own drugs to foreign pharmaceutical companies. Such deals normally have involved large Japanese drug makers licensing drugs from abroad, but now foreign drug makers are looking to Japan-based bioventures. Evec, a Japanese bioventure, was an early licenser, reaching an agreement with Boehringer Ingelheim of Germany to develop and market its antibody agent. Other Japanese bioventures have been licensing their drugs to larger Japanese drug makers. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts